tirzepatide pregnancy breastfeeding guidance Is Safe While Breastfeeding? FDA & Alternatives Mounjaro and Breastfeeding: Latest MHRA

Do not inject into the inner arm, near the armpit, or too close to the elbow or shoulder joints

Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94]

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 19902015: a systematic analysis for the global burden of disease study 2015

When you combine these findings with the metabolic benefitsbetter weight reduction, glycemic control, and effects on blood pressure and lipidsit adds up to a favorable outcome for patients. Adverse events leading to drug stoppage were higher with tirzepatide (13.2% vs 10.1%), a difference that was largely driven by gastrointestinal side effects